A Phase III, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of a Low (50-100 mg/Day) and High (150-200 mg/Day) Dose Range of Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Trial Profile

A Phase III, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of a Low (50-100 mg/Day) and High (150-200 mg/Day) Dose Range of Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2015

At a glance

  • Drugs Safinamide (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Newron Sweden AB
  • Most Recent Events

    • 13 Nov 2015 According to a Zambon media release, Xadago (safinamide) was approved as add-on therapy to levodopa (L-dopa) alone or in combination with other PD therapies for patients with Parkinson's disease in mid-to late-stage and motor fluctuations by Swissmedic on November 12, 2015.
    • 23 Jun 2015 Pooled analysis (009, 015 and MOTION) Efficacy benefits results presented at the 1st Congress of the European Academy of Neurology.
    • 18 Jun 2015 Pooled analysis (009, 015, Motion) results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top